Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vilya

Request full access

Developing a novel class of drugs that precisely target the biology of disease

Seattle, United StatesFounded 2022Biotech & Life Sciences

About Vilya

Vilya is a computational biotechnology company developing a new class of medicines.

The company's platform is based on research from the Institute of Protein Design and utilizes advanced computational methods for drug design. This technology enables the creation of novel medicines that can precisely target the biological basis of diseases.

Vilya has secured significant investment, recently expanding its Series A financing to $71 million. This capital is intended to advance the development of its computational platform and accelerate its pipeline of therapeutic candidates. The business model focuses on creating a new class of medicines to address a range of diseases, potentially through internal development or partnerships within the pharmaceutical industry.

Source: Dealroom company data

At a glance

Status
Operational
Employees
48
Open positions
3
Dealroom signal
73.1/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Core AI, Spinout, Biotech and Pharma, Generative AI, AI Drug Discovery
Technology
Artificial Intelligence, Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2024 $21M $250M Menlo Ventures · Altitude Life Science Ventures · NVentures · Madrona Venture Group ↗
SERIES AOther financing Aug 2022 $50M $200M ARCH Venture Partners ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Vilya website traffic

Latest recorded traffic for Vilya is 3.2K monthly website visits, down 67% over the last three months. Vilya's team declined 2% over the past year.

Latest monthly visits3.2K 3-month web change-67% 1-year team growth-2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Vilya in the Seattle ecosystem

Live from Dealroom

The Vilya office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Other known investors1 additional known investor

  • University of Washington Institute for Protein Design
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Vilya’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.